(Q47888446)

English

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.

scientific article published in May 1998

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

review article

1 reference

stated in

Europe PubMed Central

title

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. (English)

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

1 reference

1 reference

1 reference

Scott SD

1

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

publication date

1 May 1998

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

published in

Cancer practice

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

volume

6

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

page(s)

195-197

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

issue

3

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

cites work

Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1523-5394.1998.006003195.X

retrieved

21 January 2018

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1523-5394.1998.006003195.X

retrieved

21 January 2018

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1523-5394.1998.006003195.X

retrieved

21 January 2018

Identifiers

DOI

10.1046/J.1523-5394.1998.006003195.X

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

PubMed ID

9652253

1 reference

stated in

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/9652253

(Q47888446)

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)